Earnings call transcript: Cresco Labs tops Q2 2026 estimates as stock stays weak

Cresco Labs reported Q2 2026 revenue of $173.34M (+15% sequentially) and adjusted EPS of -$0.01 vs -$0.016 expected, beating consensus by $7.46M (+4.5%) on revenue and slightly improving losses, with adjusted EBITDA rising to $40M (23% margin). Despite better profitability and cash generation ($15M operating cash flow; $67M cash/restricted cash), the stock remained near the 52-week low at ~$0.90 and guidance called for roughly flat Q3 revenue (~$173M) with gross margin guided to the high-40s to 50% range amid ongoing pricing pressure. Management highlighted potential upside from federal rescheduling, which could remove the 280E tax burden, but near-term earnings are still expected to remain negative.

Analysis

The quarter says Cresco is one of the few MSOs with enough operating discipline to turn incremental volume into cash, which matters more than the headline EPS beat. That creates a relative winner inside a weak sector: high-quality, vertically integrated operators with real retail control and cultivation leverage should keep taking share from smaller, undercapitalized peers as pricing remains rationally brutal. The second-order effect is less about industry-wide growth and more about consolidation—state-level enforcement and tighter hemp rules would push value back toward compliant operators while starving fringe players of traffic and working capital.

The market’s refusal to rerate the stock is a clue, not an error. Investors are treating the quarter as evidence of survivability, not a durable inflection, because the next 1-2 quarters likely still show flat top-line momentum, one-off gross margin help rolling off, and financing constraints that cap M&A velocity. In the near term, the key falsifier is any slippage below roughly 20% EBITDA margin or evidence that gross margin falls back into the low-40s/high-40s once inventory and promo effects normalize; that would tell you the operating leverage story is more cyclical than structural.

Contrarian view: the consensus is probably underweighting how much optionality is embedded in 280E relief and cheaper capital, but overestimating how quickly that optionality gets monetized. This is a long-duration call on reform, not a clean earnings compounder today. If reform headlines stall, the stock can stay depressed despite good execution; if reform advances, the rerating could be fast because balance-sheet optics and taxable income would improve simultaneously. The cleanest expression is relative long quality MSO vs sector beta rather than a naked bet on legalization timing.

Key Decisions for Investors

• Tactically buy CRLBF only on weakness near the recent low base; use a tight stop if the stock cannot reclaim the $1 handle, because failure there implies the market is still valuing it as a distressed option on reform rather than an operating business.
• Pair trade: long CRLBF / short MSOS for 1-3 months. CRLBF has better demonstrated cash conversion and state-level execution; the short hedges sector-wide policy beta and reduces exposure to headline-driven multiple compression.
• If you want policy upside without taking spot risk, use small upside call spreads on CRLBF only into identifiable catalysts (Pennsylvania approval, rescheduling milestones, or federal enforcement headlines). Avoid outright long-dated calls until there is evidence Q3 margins hold despite inventory headwinds.
• Watchlist, not a trade yet: if CRLBF prints another quarter with operating cash flow > EBITDA-to-cash conversion improving and SG&A flat in dollars, re-underwrite as a consolidation winner; if not, stay out and prefer balance-sheet cleaner names.